KR20200003791A - 듀테트라베나진의 유사체, 이의 제조 및 용도 - Google Patents

듀테트라베나진의 유사체, 이의 제조 및 용도 Download PDF

Info

Publication number
KR20200003791A
KR20200003791A KR1020197030354A KR20197030354A KR20200003791A KR 20200003791 A KR20200003791 A KR 20200003791A KR 1020197030354 A KR1020197030354 A KR 1020197030354A KR 20197030354 A KR20197030354 A KR 20197030354A KR 20200003791 A KR20200003791 A KR 20200003791A
Authority
KR
South Korea
Prior art keywords
compound
deuttravenazine
pharmaceutical composition
concentration
area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197030354A
Other languages
English (en)
Korean (ko)
Inventor
쳉지 장
짐 케르
Original Assignee
오스펙스 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오스펙스 파마슈티칼스, 인코포레이티드 filed Critical 오스펙스 파마슈티칼스, 인코포레이티드
Priority to KR1020227043234A priority Critical patent/KR20230003308A/ko
Publication of KR20200003791A publication Critical patent/KR20200003791A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
KR1020197030354A 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도 Ceased KR20200003791A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227043234A KR20230003308A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
US62/471,484 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227043234A Division KR20230003308A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Publications (1)

Publication Number Publication Date
KR20200003791A true KR20200003791A (ko) 2020-01-10

Family

ID=61873991

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197030354A Ceased KR20200003791A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도
KR1020227043234A Ceased KR20230003308A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227043234A Ceased KR20230003308A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Country Status (20)

Country Link
US (4) US11813232B2 (https=)
EP (1) EP3596077A1 (https=)
JP (3) JP7608050B2 (https=)
KR (2) KR20200003791A (https=)
CN (1) CN110709398A (https=)
AR (1) AR111182A1 (https=)
AU (2) AU2018236336B2 (https=)
BR (1) BR112019018966A2 (https=)
CA (1) CA3056612A1 (https=)
CL (1) CL2019002629A1 (https=)
CO (1) CO2019011271A2 (https=)
EA (1) EA201992168A1 (https=)
IL (1) IL269132A (https=)
MX (1) MX2019010913A (https=)
PE (1) PE20191819A1 (https=)
SG (1) SG11201908477QA (https=)
TW (1) TWI772382B (https=)
UA (1) UA127052C2 (https=)
WO (1) WO2018170214A1 (https=)
ZA (1) ZA201906326B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
KR20210114946A (ko) 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US11311488B2 (en) 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP4345100A3 (en) * 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015084622A1 (en) * 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso

Also Published As

Publication number Publication date
JP2024050724A (ja) 2024-04-10
JP7608050B2 (ja) 2025-01-06
US11179386B2 (en) 2021-11-23
CN110709398A (zh) 2020-01-17
TW201840317A (zh) 2018-11-16
IL269132A (en) 2019-11-28
CA3056612A1 (en) 2018-09-20
JP2023010754A (ja) 2023-01-20
AU2018236336B2 (en) 2022-02-24
JP7631572B2 (ja) 2025-02-18
SG11201908477QA (en) 2019-10-30
US20220088006A1 (en) 2022-03-24
BR112019018966A2 (pt) 2020-04-22
US20220040170A1 (en) 2022-02-10
WO2018170214A1 (en) 2018-09-20
AU2022203369B2 (en) 2024-04-04
US12502385B2 (en) 2025-12-23
AU2022203369A1 (en) 2022-06-09
US20180263972A1 (en) 2018-09-20
NZ757789A (en) 2024-08-30
TWI772382B (zh) 2022-08-01
EA201992168A1 (ru) 2020-03-16
CL2019002629A1 (es) 2020-01-24
KR20230003308A (ko) 2023-01-05
AU2018236336A1 (en) 2019-10-24
JP2020510073A (ja) 2020-04-02
US20200016148A1 (en) 2020-01-16
UA127052C2 (uk) 2023-03-29
MX2019010913A (es) 2020-01-20
EP3596077A1 (en) 2020-01-22
US11813232B2 (en) 2023-11-14
ZA201906326B (en) 2022-12-21
PE20191819A1 (es) 2019-12-27
CO2019011271A2 (es) 2020-02-28
AR111182A1 (es) 2019-06-12

Similar Documents

Publication Publication Date Title
JP7631572B2 (ja) デューテトラベナジンの類似体、その調製及び使用
EP3056205A1 (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
JP2014503480A (ja) ジュウテリウムリッチなラサギリン
CN103930100A (zh) R(+)-n-甲基-炔丙基-氨基茚满
KR20140074388A (ko) 라사길린 시트라마이드
AU2013259779B2 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
EP2094675B1 (en) A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
CN111943958A (zh) 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用
HK40018479A (en) Analogs of deutetrabenazine, their preparation and use
EA044519B1 (ru) Способ получения готовой лекарственной формы деутетрабеназина, содержащая его композиция и способ лечения субъекта, страдающего гиперкинетическим двигательным расстройством
TW202542164A (zh) 治療過動性運動障礙之化合物
AU2024409099A1 (en) Compounds for treatment of a hyperkinetic movement disorder
JPH05504765A (ja) 神経学的疾患を治療するための4,4′―〔9h―フルオレン―9―イリデンビス(メチレン)〕ビスピリミジン
CN118984818A (zh) 环己酮化合物的晶型
NZ624206B2 (en) R(+)-n-formyl-propargyl-aminoindan

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210315

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20211119

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220308

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220907

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220308

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221208